Jefferies Downgrades Aevi Genomic Medicine to Hold with Price Target $2.5

Brokerage firm Jefferies Downgrades its rating on Aevi Genomic Medicine(GNMX). As per the latest information, Jefferies Lowers the price target to $2.5 per share from a prior target of $10. The shares have been rated Hold. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at Jefferies was issued on Mar 21, 2017 in a research report to their Investors and Clients.

Add Comment